When AI Capex Pays: The Case for MSFT at $492
Azure's 43% growth quarter ended a year-long debate. Now ask whether the market has already priced it in.
Azure's 43% growth quarter ended a year-long debate. Now ask whether the market has already priced it in.
Bessent’s Treasury twist and the GENIUS Act are reshaping the short end. Here is what cash holders should know.
Taiwan’s record $35 billion defense budget puts a price on tail risk. The question is whether chip stocks reflect any…
Healthcare has outrun SOXX since June. The flows have barely started.
The Jevons Paradox is alive in the GPU market. Falling token prices expand the addressable universe of AI workloads, and…
The speed claims may hold. The margin path and customer concentration are what investors are debating.
Three days, $880 billion in bilateral trade, and a 96-year-old legal weapon nobody has ever fired. Here is what the…
A March 2027 trial date, a $7 million daily clock, and a March 4 end date have turned this into…
The Hassabis shift and the Dean exit are symptoms. The chip allocation fight is the disease.
The refiner trade is the cheapest seat at the most expensive pump in recorded history.